PubMed Health⌕ Search

PubMed · 1163554

PACP regional quality control program: a general survey.

Abstract

A regional quality control program operated by the Pennsylvania Association of Clinical Pathologists is described. About 120 laboratories in Pennsylvania and a few neighboring states participated in the program. Two 1000-liter lots of pooled normal and abnormal sera meeting or exceeding the specifications of the National Committee of Clinical Laboratory Standards and the College of American Pathologists were prepared and lyophilized. Participating laboratories determined each constituent in the sera every day for a year, from March 1973 to March 1974. The data was processed by a computer. The inter- and intra-laboratory reports containing the mean, standard deviation, coefficient of variation, Youden plots, etc. for each constituent were made available to all the participating laboratories. Practical applications of these statistical parameters in evaluating the quality of the performance of the laboratories are discussed.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Dharan. 1975. PACP regional quality control program: a general survey.. https://pubmed.ncbi.nlm.nih.gov/1163554/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Detection of Delta9-tetrahydrocannabinolic acid A in human urine and blood serum by LC-MS/MS.

Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) is the precursor of Delta9-tetrahydrocannabinol (Delta9-THC) in hemp plants. During smoking, the non-psychoactive Delta9-THCA-A is converted to Delta9-THC, the main psychoactive component of marihuana and hashish. Although the decarboxylation of Delta9-THCA-A to Delta9-THC was assumed to be complete--which means that no Delta9-THCA-A should be detectable in urine and blood serum of cannabis consumers--we found Delta9-THCA-A in the urine and blood serum samples collected from police controls of drivers suspected for driving under the influence of drugs (DUID). For LC-MS/MS analysis, urine and blood serum samples were prepared by solid-phase extraction. Analysis was performed with a phenylhexyl column using gradient elution with acetonitrile. For detection of Delta9-THCA-A, the mass spectrometer (MS) (SCIEX API 365 triple-quadrupole MS with TurboIonSpray source) was operated in the multiple reaction monitoring (MRM) mode using the following transitions: m/z357 --> 313, m/z357 --> 245 and m/z357 --> 191. Delta9-THCA-A could be detected in the urine and blood serum samples of several cannabis consumers in concentrations of up to 10.8 ng/ml in urine and 14.8 ng/ml in serum. The concentration of Delta9-THCA-A was below the Delta9-THC concentration in most serum samples, resulting in molar ratios of Delta9-THCA-A/Delta9-THC of approximately 5.0-18.6%. Only in one case, where a short elapsed time between the last intake and blood sampling is assumed, the molar ratio was 18.6% in the serum. This indicates differences in elimination kinetics, which need to be investigated in detail.

Blood Chemical Analysis↗